Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared a post on X:
“Tom Powles presents prospective ctDNA selected patients with resected bladder cancer – Atezolizumab vs placebo, showing DFS and OS benefit. Need serial ctDNA assessment and treat patients with molecular residual disease.
Kudos for IMvigor011 trial with concurrent NEJM pub today – certainly practice changing for our pts with bladder cancer!”
Title: ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Authors: Thomas Powles, Ariel G. Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Sergio Bracarda, Jørgen Bjerggaard Jensen, Lydia Makaroff, Shusuan Jiang, Ja Hyeon Ku, Se Hoon Park, Oscar Reig Torras, Dingwei Ye, Marco Maruzzo, Andrea Necchi, Rafael Morales-Barrera, Emilio Francesco Giunta, Jae Lyun Lee, Giampaolo Tortora, Yüksel Ürün, Lukasz Dolowy, Dilek Erdem, Alvaro Pinto, Fabricio Grando, Wei Zou, Zoe June Assaf, Jacqueline Vuky, Viraj Degaonkar, Elizabeth E. Steinberg, Joaquim Bellmunt, Jürgen E. Gschwend
Read the Full Article in The New England Journal of Medicine.
More posts featuring Tian Zhang on OncoDaily.
